Suzhou Ribo Life Science, a company focused on small interfering RNA drugs, raised $39 million in a B round led by China's State Development and Investment Corporation. Founded in 2007, Ribo is developing siRNA drugs for hepatitis B, hyperlipidaemia and liver cancer. In 2012, Ribo formed a China JV with US-based Quark Pharma, also a siRNA company. Three years later, the CFDA approved the JV's Ischemic Optic Neuropathy siRNA drug for use in China.
Source: ChinaBio Today
Please to leave a comment.
Over the years, investors have seen how exciting opportunities in innovation have matured into solid investments. Advances in AI, Big Data, Clean Technology and Health Care have all led ... Event Info